Home › Funds › ARMISTICE CAPITAL, LLC › DYN

ARMISTICE CAPITAL, LLC position in DYN

DYNE THERAPEUTICS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 3,087,226 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$68.6M, representing 0.90% of its reported portfolio and ranking #11 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.09M sh
Reported value held$68.57M
Portfolio Weight0.90%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's DYN position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in DYN in Q3 2023 at 1,200,000 shares (US$10.8M). The position peaked in Q2 2026 at 3,087,226 shares, worth US$68.6M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,087,226 shares valued at US$68.6M — a reduction of -87,884 shares quarter over quarter.. Notable position changes include a 31% trim in Q4 2023 (shares rose 113% over the following quarter), a 187% increase in Q1 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.20M $10.75M New
Q4 2023 824.00K $10.96M Reduce
Q1 2024 1.00M $28.39M Add
Q2 2024 970.89K $34.26M Reduce
Q3 2024 1.16M $41.49M Add
Q4 2024 964.52K $22.72M Reduce
Q1 2025 2.77M $28.95M Add
Q2 2025 2.56M $24.37M Reduce
Q3 2025 3.06M $38.76M Add
Q4 2025 3.25M $63.56M Add
Q1 2026 3.18M $57.56M Reduce
Q2 2026 3.09M $68.57M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held DYN?

ARMISTICE CAPITAL, LLC has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in DYN?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 3.09M shares of DYN (DYNE THERAPEUTICS INC), valued at $68.57M, representing 0.90% of its reported portfolio and ranking #11.

Has ARMISTICE CAPITAL, LLC been buying or selling DYN?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in DYN. The position peaked in Q2 2026 at 3.09M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.